公开(公告)号：US12090200B2

公开(公告)日：2024-09-17

申请号：US17089468

申请日：2020-11-04

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen

IPC: A61K39/12 ,  A61K39/21 ,  C12N15/113 ,  C12N15/86 ,  A61K39/00

CPC classification number: A61K39/21 ,  A61K39/12 ,  C12N15/1132 ,  C12N15/1138 ,  C12N15/86 ,  A61K2039/5252 ,  A61K2039/5258 ,  A61K2039/545 ,  A61K2039/55522 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/351 ,  C12N2330/51 ,  C12N2710/24143 ,  C12N2740/16043 ,  C12N2740/16234

Abstract: The present invention relates generally to immunotherapy for preventing HIV infection in HIV-negative individuals. In particular, the methods include methods for making cells resistant to HIV and administering an immune therapy to an HIV-negative subject to prevent an HIV infection.

公开(公告)号：US20240238406A1

公开(公告)日：2024-07-18

申请号：US18540621

申请日：2023-12-14

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Gary Mansfield

IPC: A61K39/21 ,  A61K31/7105 ,  A61K35/12 ,  A61K35/14 ,  A61K35/15 ,  A61K35/17 ,  A61K39/00 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/715 ,  C12N5/078 ,  C12N5/0783 ,  C12N7/00 ,  C12N15/11 ,  C12N15/113 ,  C12N15/86

CPC classification number: A61K39/21 ,  A61K31/7105 ,  A61K35/14 ,  A61K39/12 ,  A61K39/39 ,  A61K45/06 ,  A61P31/18 ,  C07K14/7158 ,  C12N5/0634 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/111 ,  C12N15/1132 ,  C12N15/1138 ,  C12N15/86 ,  A61K2035/124 ,  A61K35/15 ,  A61K35/17 ,  A61K2039/5156 ,  A61K2039/545 ,  A61K2039/55561 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/51 ,  C12N2510/00 ,  C12N2710/24143 ,  C12N2740/15021 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12N2740/15052 ,  C12N2740/16022 ,  C12N2740/16034 ,  C12N2740/16043

Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

公开(公告)号：US20240141374A1

公开(公告)日：2024-05-02

申请号：US18227775

申请日：2023-07-28

Applicant: American Gene Technologies International Inc.

Inventor： Haishan Li ,  Tyler Lahusen ,  Charles David Pauza

IPC: C12N15/86

CPC classification number: C12N15/86

Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.

公开(公告)号：US20230340531A1

公开(公告)日：2023-10-26

申请号：US18051821

申请日：2022-11-01

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Mei-Ling Liou

IPC: C12N15/86 ,  A61K31/675 ,  A61K31/7105 ,  A61K38/16 ,  C12N5/0783 ,  C12N15/113

CPC classification number: C12N15/86 ,  A61K31/675 ,  A61K31/7105 ,  A61K38/16 ,  C12N5/0636 ,  C12N15/113 ,  A61K48/00

Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

公开(公告)号：US20190218573A1

公开(公告)日：2019-07-18

申请号：US16218010

申请日：2018-12-12

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Jeff Galvin

IPC: C12N15/86 ,  A61K39/39 ,  C12N7/00 ,  C12N15/113 ,  A61P31/18 ,  C12N5/078 ,  A61K35/14

CPC classification number: C12N15/86 ,  A61K35/14 ,  A61K35/15 ,  A61K39/12 ,  A61K39/39 ,  A61K2035/124 ,  A61K2039/55561 ,  A61P31/18 ,  C12N5/0634 ,  C12N5/0636 ,  C12N7/00 ,  C12N15/1132 ,  C12N15/1138 ,  C12N2310/141 ,  C12N2320/32 ,  C12N2330/51 ,  C12N2510/00 ,  C12N2740/15021 ,  C12N2740/15034 ,  C12N2740/15043 ,  C12N2740/15052

Abstract: The present invention relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include in vivo and/or ex vivo enrichment of HIV-specific CD4+ T cells.

公开(公告)号：US20240279678A1

公开(公告)日：2024-08-22

申请号：US17908509

申请日：2021-03-03

Applicant: American Gene Technologies International Inc.

Inventor： Haishan Li ,  Tyler Lahusen ,  Charles David Pauza

IPC: C12N15/86 ,  A61K35/17 ,  A61K39/00 ,  A61K39/21 ,  C07K14/73 ,  C07K16/10 ,  C12N5/0783

CPC classification number: C12N15/86 ,  A61K35/17 ,  A61K39/21 ,  A61K39/461 ,  A61K39/464838 ,  C07K14/70514 ,  C07K16/1045 ,  C12N5/0636 ,  C07K2317/76 ,  C12N2740/16043 ,  C12N2740/16052 ,  C12N2830/008

Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or inhibition of HIV. In embodiments, a viral vectors are disclosed that comprise therapeutic cargo portions comprising a nucleotide sequence that encodes at least one soluble exogenous factor capable of inhibiting HIV infection, and a T cell-responsive promoter that regulates expression of the nucleotide sequence.

公开(公告)号：US20240115604A1

公开(公告)日：2024-04-11

申请号：US18227747

申请日：2023-07-28

Applicant: American Gene Technologies International Inc.

Inventor： Haishan Li ,  Charles David Pauza

IPC: A61K35/17 ,  A61K38/16 ,  A61K39/21 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K38/162 ,  A61K39/21 ,  C12N5/0636 ,  C12N2310/141

Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include purifying peripheral blood mononuclear cells (PBMC) from a source, stimulating the PBMC with at least one HIV-specific peptide, depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, CD4+ T cells, γδ cells, NK cells, B cells, T regulatory cells, and NKT cells, transducing the depleted PBMC with a viral delivery system encoding at least one genetic element, culturing the transduced PBMC for at least one day, and harvesting the cultured PBMC.

公开(公告)号：US11534450B2

公开(公告)日：2022-12-27

申请号：US16988427

申请日：2020-08-07

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Mei-Ling Liou

IPC: A61K31/7105 ,  C12N15/113 ,  C12N15/86 ,  A61P35/02 ,  A61K47/68 ,  A61K47/69 ,  A61K31/675 ,  C12Q1/68

Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

公开(公告)号：US20210015868A1

公开(公告)日：2021-01-21

申请号：US17042043

申请日：2019-03-27

Applicant: American Gene Technologies International Inc.

Inventor： Haishan Li ,  Charles David Pauza

IPC: A61K35/17 ,  A61K38/16 ,  A61K39/21 ,  C12N5/0783

Abstract: The present disclosure relates generally to immunization and immunotherapy for the treatment or prevention of HIV. In particular, the methods include purifying peripheral blood mononuclear cells (PBMC) from a source, stimulating the PBMC with at least one HIV-specific peptide, depleting at least one subset of cells from the PBMC, wherein the at least one subset of cells comprises any one or more of CD8+ T cells, CD4+ T cells, γδ cells, NK cells, B cells, T regulatory cells, and NKT cells, transducing the depleted PBMC with a viral delivery system encoding at least one genetic element, culturing the transduced PBMC for at least one day, and harvesting the cultured PBMC.

公开(公告)号：US10772905B2

公开(公告)日：2020-09-15

申请号：US16530908

申请日：2019-08-02

Applicant: American Gene Technologies International Inc.

Inventor： Charles David Pauza ,  Haishan Li ,  Tyler Lahusen ,  Mei-Ling Liou

IPC: A61K31/7105 ,  C12N15/113 ,  C12N15/86 ,  A61K47/69 ,  A61P35/02 ,  A61K47/68 ,  A61K31/675

Abstract: The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.